索拉非尼治疗晚期原发性肝癌的研究现状  

The Research Status of Sorafenib in Treatment of the Advanced Hepatocellular Carcinoma

作　　者：杨学芳 李雷[1] 沈世林[1] 王文辉[1] 

机构地区：[1]兰州大学第一医院中西医结合介入科,兰州730000 [2]甘肃中医学院,兰州730000

出　　处：《医学综述》2016年第5期918-921,共4页Medical Recapitulate

摘　　要：原发性肝癌是我国最常见的恶性肿瘤之一,往往被诊断时已处于中晚期,治疗手段非常有限。索拉非尼(多吉美)是一种多靶向分子药物,其作为晚期肝癌一线的标准治疗方式,已逐渐在临床上开展应用,并且取得了一定的临床疗效。大量的临床随机试验已证明,其能延长患者的生存期,使患者获益。Hepatocellular carcinoma is one of the most common malignant tumors in China, which is often diagnosed in the middle and advanced stage,when the treatments are very limited. Sorafenib（Nexavar） is a kind of multi-target drug molecule which is the first-line standard treatment for advanced hepatoceUular carcinoma,which has been gradually carried out in clinical application and has achieved certain satist＇actory clinical efficacy. A large number of cliinical randomized trials have proved it can prolong the survival of the patients, bringing benefits to them.

关 键 词：原发性肝癌 索拉非尼 肝动脉化疗栓塞术 

分 类 号：R735.7[医药卫生—肿瘤]